Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

5/11/23 9:25:42 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Medical/Dental Instruments

Health Care

Get the next $ESPR alert in real time by email

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Sensus Healthcare

Esperion Therapeutics

TCR2 Therapeutics

Check This Out: Investor Sentiment Declines Slightly Following Inflation Data

Don’t forget to check out our premarket coverage here

Get the next $ESPR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ESPR
$SRTS
$TCRR

Company	Date	Price Target	Rating	Analyst
Sensus Healthcare Inc. $SRTS	11/15/2024	$12.00 → $14.00	Buy	Maxim Group
Esperion Therapeutics Inc. $ESPR	6/20/2024	$2.50	Neutral → Underperform	BofA Securities
Esperion Therapeutics Inc. $ESPR	1/3/2024		Buy → Neutral	BofA Securities
Esperion Therapeutics Inc. $ESPR	11/20/2023		Neutral	JP Morgan
Esperion Therapeutics Inc. $ESPR	8/1/2023		Under Perform → Market Perform	Northland Capital
Esperion Therapeutics Inc. $ESPR	6/15/2023	$1.25 → $4.00	Underperform → Buy	BofA Securities
Esperion Therapeutics Inc. $ESPR	3/16/2023	$1.00	Market Perform → Under Perform	Northland Capital
Esperion Therapeutics Inc. $ESPR	3/16/2023	$8.00 → $1.50	Neutral → Underperform	BofA Securities

More analyst ratings

$ESPR
$SRTS
$TCRR
Financials

Live finance-specific insights

REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
11/17/24 8:32:25 PM ET
$SRTS
Medical/Dental Instruments
Health Care
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
11/14/24 12:06:41 PM ET
$SRTS
Medical/Dental Instruments
Health Care
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "The year to date has been transformational for Es
11/7/24 6:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and ca
11/21/24 8:00:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcome
11/18/24 10:30:00 AM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
11/17/24 8:32:25 PM ET
$SRTS
Medical/Dental Instruments
Health Care

$ESPR
$SRTS
$TCRR
Leadership Updates

Live Leadership Updates

Sensus Healthcare Announces Retirement of Director Samuel O'Rear
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv
2/1/24 8:00:00 AM ET
$SRTS
Medical/Dental Instruments
Health Care
Esperion Appoints Ben Halladay Chief Financial Officer
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive management team and report to Sheldon Koenig, President and Chief Executive Officer. "We are thrilled to have Ben take on this expanded role on the Esperion leadership team with his promotion to CFO," said Sheldon Koenig, President and CEO of Esperion. "Ben has made significant contributions since joining the company in 2020, supporting our finance organization during a tra
11/16/22 4:00:00 PM ET
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. "We are excited to announce Eric Sullivan is joining the TCR2 team as Chief Financial Officer," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Eric brings a tremendous breadth of financial,
6/27/22 6:45:00 AM ET
$TCRR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care